Logan Coy Related postsAn Open-Label, Randomized, Controlled Phase 3 Study of Sigvotatug Vedotin with Pembrolizumab vs Pembrolizumab Monotherapy as First-Line Treatment in PD-L1 High Advanced NSCLC (BE6A LUNG-02)September 11, 2026A Phase 1b/2 Open-Label Study of APVO436 in Combination with Venetoclax and Azacitidine in Newly Diagnosed Acute Myeloid Leukemia (AML)September 11, 2026A Phase 1, Open-Label, Multicenter Study of the Pharmacokinetics and Safety of Pralatrexate in Advanced Solid Tumor or Hematological Malignancy with Normal or Mild/Moderate/Severe Hepatic ImpairmentSeptember 11, 2026 Previous postA Phase 1/2a, Open-Label Study of SA53-OS, an MDM2 Inhibitor, in Locally Advanced or Metastatic p53 Wild-Type Solid Tumors